Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313 Journal Article

Local Library Link: Find It @ Loyola

Authors: Persky, D. O.; Miller, T. P.; Unger, J. M.; Spier, C. M.; Puvvada, S.; Stea, B. D.; Press, O. W.; Constine, L. S.; Barton, K. P.; Friedberg, J. W.; LeBlanc, M; Fisher, R. I.
Article Title: Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313
Abstract: In the S0313 trial, we evaluated the impact of adding ibritumomab tiuxetan consolidation to 3 cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy plus involved field radiotherapy (IFRT) in patients with limited-stage aggressive B-cell non-Hodgkin lymphoma (LD-NHL). Patients with at least 1 stage-modified adverse risk factor (nonbulky stage II, age >60 years, elevated lactate dehydrogenase, or World Health Organization performance status of 2) were treated with CHOP on days 1, 22, and 43, followed 3 weeks later by 40 to 50 Gy of IFRT. An ibritumomab tiuxetan regimen was initiated 3 to 6 weeks following IFRT. Forty-six patients were registered and eligible, with median follow-up of 7.3 years. The progression-free survival estimate is 89% at 2 years, 82% at 5 years, and 75% at 7 years. The overall survival estimate is 91% at 2 years, 87% at 5 years, and 82% at 7 years. Grade 4 adverse events occurring more than once included neutropenia (8), leukopenia (5), and lymphopenia (2). Febrile neutropenia was observed in 4 patients. No cases of treatment-related myeloid neoplasms were noted. In conclusion, patients with high-risk LD-NHL treated with 3 cycles of CHOP plus IFRT followed by ibritumomab tiuxetan consolidation had outcomes that compare favorably to our historical experience. The clinical trial was registered at www.clinicaltrials.gov as #NCT00070018.
Journal Title: Blood
Volume: 125
Issue: 2
ISSN: 1528-0020; 0006-4971
Publisher: by The American Society of Hematology  
Journal Place: United States
Date Published: 2015
Start Page: 236
End Page: 241
Language: eng
DOI/URL:

10.1182/blood-2014-06-584623
Notes: LR: 20150407; CI: (c) 2015; ClinicalTrials.gov/NCT00070018; GR: CA04919/CA/NCI NIH HHS/United States; GR: CA11083/CA/NCI NIH HHS/United States; GR: CA12612/CA/NCI NIH HHS/United States; GR: CA12644/CA/NCI NIH HHS/United States; GR: CA20319/CA/NCI NIH HHS/United States; GR: CA32102/CA/NCI NIH HHS/United States; GR: CA35178/CA/NCI NIH HHS/United States; GR: CA35192/CA/NCI NIH HHS/United States; GR: CA35431/CA/NCI NIH HHS/United States; GR: CA38926/CA/NCI NIH HHS/United States; GR: CA45807/CA/NCI NIH HHS/United States; GR: CA46282/CA/NCI NIH HHS/United States; GR: CA67663/CA/NCI NIH HHS/United States; GR: P01 CA044991/CA/NCI NIH HHS/United States; GR: P01 CA044991/CA/NCI NIH HHS/United States; GR: R01 CA076287/CA/NCI NIH HHS/United States; GR: R01 CA076287/CA/NCI NIH HHS/United States; GR: U10 CA038926/CA/NCI NIH HHS/United States; GR: U10 CA180819/CA/NCI NIH HHS/United States; JID: 7603509; 0 (Antibodies, Monoclonal); 0 (ibritumomab tiuxetan); 57-22-7 (Vincristine); 80168379AG (Doxorubicin); 8N3DW7272P (Cyclophosphamide); VB0R961HZT (Prednisone); CHOP protocol; OID: NLM: PMC4287635 [Available on 01/08/16]; PMCR: 2016/01/08 00:00; 2014/11/13 [aheadofprint]; ppublish